Further, olaparib plus enzalutamide treatment inhibited PC tumor growth in subcutaneous patient-derived xenograft tumor models (MDA PCa 133-4, AR-positive) as well as in two orthotopic PC cell lines (AR-positive VCaP and CWR22Rv1)[34]. The gene discussed is AR; the disease is pachyonychia congenita.